Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) is now available.
Jacobio Pharmaceuticals announced the presentation of preclinical data for their pan-KRAS inhibitor, JAB-23E73, at the AACR-NCI-EORTC 2025 conference. The data indicates that JAB-23E73 shows strong antitumor activity and good tolerability in KRAS-driven cancer models, with ongoing Phase I trials in China and the U.S. This advancement could enhance Jacobio’s position in the oncology sector, potentially impacting stakeholders positively if successful.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a company focused on developing innovative products and solutions to improve patient health. Their research pipeline targets novel molecular pathways including KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. Jacobio aims to be a global leader in drug research and development, with R&D centers located in Beijing, Shanghai, and Boston.
Average Trading Volume: 9,129,339
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.55B
See more insights into 1167 stock on TipRanks’ Stock Analysis page.